Abstract 143: Pearls and Pitfalls of Performance-linked Reimbursement Plans for Novel Drugs: The Case of Sacubitril-Valsartan [Session Title: Poster Session AM]

Conclusion: PLR plans require outcomes tightly associated with treatment value and minimally influenced by unrelated uncertainty. Both sides must agree on a predictable population and limit asymmetric selection. For rare outcomes, plans should evaluate population event rates or surrogate measures that consistently reflect the clinical benefit.

Source: Circulation: Cardiovascular Quality and Outcomes - April 5, 2018 Category: Cardiology Authors: Sandhu, A. T., Heidenreich, P. A. Tags: Session Title: Poster Session AM Source Type: research